U.S. Markets closed

A Financial Overview of Supernus Pharmaceuticals in September

Daniel Collins
A Financial Overview of Supernus Pharmaceuticals in September

In the second quarter, Supernus Pharmaceuticals (SUPN) reported net revenues of $99.5 million compared to $75.8 million in the second quarter of 2017. In the first half, Supernus Pharmaceuticals generated net revenues of $190.0 million compared to $133.4 million in the first half of 2017.